Frequently Asked Questions
Answers about regenerative medicine procedures, aftercare, pain control, and recovery — from Sean Mulvaney, MD.
Preparing for Your Procedure
1.How can I optimize conditions before my procedure?+
2.What if I am taking anticoagulation therapy or blood-thinning drugs?+
3.Are there medications that I should hold before my procedure, or that may interfere with my procedure?+
If you have any questions, please talk to Dr. Mulvaney about any decisions to hold a medication around the time of your procedure.
A literature review was conducted to identify which medications have compelling, evidence-based reasons to be held before regenerative medicine procedures, versus those commonly assumed to interfere but lacking supporting data. Several agents often held out of caution — statins, biologic DMARDs, and methotrexate — do not clear the evidentiary bar for a routine hold recommendation.
| Medication / Class | Recommendation | Basis / Level of Evidence |
|---|---|---|
| NSAIDs / other anti-inflammatories | HOLD | Well-established suppression of the early inflammatory phase required for platelet/growth-factor signaling; standard peri-procedural practice. |
| Aspirin (peri-PRP) | HOLD | Established interference with platelet activation central to PRP's mechanism of action. |
| Therapeutic anticoagulants | HOLD (case-by-case) | Established bleeding risk. Not all agents equal: LMWH (tinzaparin) also directly impairs MSC proliferation in vitro; fondaparinux appears MSC-neutral — a reasonable substitution if anticoagulation cannot be paused. |
| Fluoroquinolones | HOLD / AVOID | Direct tenocyte and collagen toxicity via MMP upregulation; ~4x increased tendinopathy risk and ~2.5x rupture risk, compounded by concurrent corticosteroid use. Rarely first-line antibiotics regardless. |
| Nicotine / smoking | HOLD (cessation) | Vasoconstriction, blunted VEGF-driven angiogenesis, and direct impairment of platelet growth-factor release — hits PRP's mechanism directly. 2–4 week cessation window best supported, though not RCT-defined. |
| Statins (HMG-CoA reductase inhibitors) | NO ROUTINE HOLD | Evidence is genuinely mixed: theoretical antiplatelet effect and a tendon MMP/tendinopathy signal exist, but counterbalanced by pro-angiogenic (EPC/eNOS) effects and known harms of stopping in cardiac-risk patients. No procedure-specific outcome data. Consider individualizing only for a patient with active tendinopathy or prior statin-associated tendon injury. |
| Biologic DMARDs (TNF inhibitors, IL-targeted agents) | NO ROUTINE HOLD | Orthopedic surgery literature shows discontinuation raises flare risk without clearly improving outcomes. The infection-risk rationale for holding applies far more to open/implant surgery than to a needle-based injection procedure. |
| Methotrexate | NO ROUTINE HOLD | In vitro data shows dose-dependent inhibition of MSC osteogenesis/chondrogenesis, but this is contradicted by stronger clinical evidence: an RCT in RA surgical patients found no difference in complications between continuing and suspending MTX, and continuing significantly reduced flare rates. Two systematic reviews concur. |
| Non-fluoroquinolone antibiotics | NO ROUTINE HOLD | No compelling data supporting withholding standard antibiotic classes before an orthobiologic procedure. |
Key Takeaway
Of the medications frequently questioned in this context, only four have compelling evidence supporting a hold: NSAIDs, aspirin/antiplatelet-anticoagulant agents, fluoroquinolones, and nicotine. Statins, biologic DMARDs, methotrexate, and non-fluoroquinolone antibiotics do not have evidence supporting routine discontinuation.
References
- Grennan DM, et al. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis. 2001;60:214-217.
- Effect of methotrexate in post-operative wound healing in rheumatoid patients undergoing foot and ankle surgery. ISRCTN86123456.
- Assessment and Comparison of the Efficacy of Methotrexate, Prednisolone, Adalimumab, and Tocilizumab on Multipotency of Mesenchymal Stem Cells. PMC7348038.
- Stopping Biologics Before Surgery May Raise Flare Risk in RA. Rheumatology Advisor, citing Arthritis Research & Therapy (2026).
- Perioperative Management of Biologic and Targeted Synthetic DMARDs in Orthopedic Surgery: Balancing Infection Risk and Disease Control. Microorganisms 2026;14:398.
- To stop or not to stop: what should we be doing with biologic DMARDs when patients undergo orthopaedic surgery? PMC8493102.
- Dose Tapering and Discontinuation of Biologic DMARDs in Axial Spondyloarthritis: A Narrative Review. Curr Rheumatol Rep. 2024. DOI: 10.1007/s11926-024-01137-w.
- Is Fluoroquinolone Exposure after Primary Tendon Repair Associated with Higher Rates of Reoperations? A Matched Cohort Study. Orthopedic Reviews, 2025.
- Short-Term Exposure to Ciprofloxacin Reduces Proteoglycan Loss in Tendon Explants. PMC9777606.
- Ciprofloxacin reduces tenocyte viability and proteoglycan synthesis in short-term explant cultures of equine tendon. PMC8411937.
- Positive Association Between Fluoroquinolone Exposure and Tendon Disorders: A Nationwide Population-Based Cohort Study in Taiwan. PMC8978711.
- Statin treatment increases the clinical risk of tendinopathy through matrix metalloproteinase release. Scientific Reports. 2019;9:17958.
- Effects of Statin Treatment on the Development of Tendinopathy: A Nationwide Population-Based Cohort Study. PMC10350772.
- Statins: bitter enemies of tendons or not? A systematic review of clinical evidence. PubMed PMID: 41182304.
- Tobert JA. Tendinopathy and Tendon Rupture Associated with Statins. PubMed PMID: 27490216.
- HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. PMC209365.
- Statins, HMG-CoA Reductase Inhibitors, Improve Neovascularization by Increasing the Expression Density of CXCR4 in Endothelial Progenitor Cells. PMC4550447.
- HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmenting platelet-derived nitric oxide release in rats. PubMed PMID: 15772528.
- Effects of Antithrombotic Drugs Fondaparinux and Tinzaparin on In Vitro Proliferation and Osteogenic and Chondrogenic Differentiation of Bone-Derived Mesenchymal Stem Cells. J Orthop Res. 2011;29:1327-1335.
- Why You Should Stop Smoking Before Your PRP Treatment. Ubie Doctor's Note, 2026.
- Orthopedic Surgery Complication Risk Associated with Smoking Cessation and Use of Nicotine Replacement Therapies: A Systematic Review. NCBI Bookshelf NBK595265.
- The influence of smoking and alcohol on bone healing: Systematic review and meta-analysis of non-pathological fractures. PMC8571530.
4.Does Dr. Mulvaney treat teenagers?+
5.Are you put to sleep or sedated for the procedures?+
6.What should I wear for this treatment?+
7.Can someone be in the room with me?+
8.How long does a treatment usually take?+
9.Can I drink alcohol the night before a procedure? How about after?+
10.Can I get a stellate ganglion block and a musculoskeletal treatment on the same day?+
Recovery & Aftercare
11.When can I shower after a procedure?+
12.Should I use ice or heat after my treatment?+
13.What can I use for pain control after a regenerative medicine procedure?+
14.How should I control the inflammation after a regenerative medicine procedure?+
15.Do I need a driver after my procedure?+
16.Will I be on crutches or in a sling after my procedure?+
17.How can I optimize my healing response?+
18.When will I follow up?+
19.What happens if I do not get the results I hoped for after a procedure?+
20.Can I go swimming or do water aerobics after a treatment?+
Returning to Movement
21.Will I do physical therapy after my procedure? If so, when?+
22.I'm almost feeling better — when can I return to my sport or activity?+
23.How do I start returning to running?+
Returning to running works best as a criteria-based, gradual progression rather than jumping straight back into your old routine. Before starting, you should be able to walk briskly for 30 minutes pain-free with normal gait mechanics, have full pain-free range of motion in the treated area, and tolerate light hopping or impact without pain or swelling.
A standard walk-run progression:
| Phase | Walk | Jog | Repeats | Days/Week |
|---|---|---|---|---|
| 1 | 4 min | 1 min | 3–6 | 2–3 |
| 2 | 3 min | 2 min | 3–6 | 2–3 |
| 3 | 2 min | 3 min | 3–6 | 2–3 |
| 4 | 1 min | 4 min | 3–6 | 2–3 |
| 5 | — | 30 min continuous | 1 | 3 |
- Do a 5–10 minute dynamic warm-up before each session, and take at least one rest day between running days.
- Run at a comfortable, easy effort — this isn't the phase for pace work.
- Only advance to the next phase once you can complete a full session pain-free, with no increased soreness or swelling afterward.
- Stop and back off if you get sharp pain, pain that worsens as you run, or pain significant enough to change your gait — talk to Dr. Mulvaney or your physical therapist before continuing.
- Once you complete Phase 5, increase weekly mileage by roughly 10% per week rather than jumping back to your prior volume all at once.
- Save speed work and hills for once you're back to 50–60% of your pre-injury weekly mileage; normal training can typically resume around 75–80%.
This is a general, evidence-informed framework — a physical therapist can tailor the pace of progression to your specific injury, running mechanics, and prior training level. Based on established graduated-return-to-running research, including Buist et al., Am J Sports Med. 2008;36:33-39, and Bredeweg et al., Br J Sports Med. 2012;46:865-870.
Payment
24.What form of payment does the ROSM Annapolis office take?+
25.Are regenerative treatments covered by most medical insurance companies?+
26.Can I use my FSA or HSA account to pay for regenerative medicine treatments?+
27.Do you offer CareCredit or any other form of payment plan?+
Still Have Questions?
Call our Annapolis office Monday through Friday, 8 AM to 5 PM.

